The stability of total (t) and free (f) prostate-specific antigen (PSA) in male serum specimens stored at –70°C or lower temperature for 4.7 to 4.9 years was studied. Until now, the stability of these analytes in serum has not been evaluated systematically beyond 2 years of storage at –70°C. Aliquots of frozen serum were thawed in 2001 and 2006 and assayed for tPSA and fPSA using a Dade Behring Dimension(r) RxL analyzer and reagents. tPSA values ranged from 0.07 to 69.94 and 0.00 to 69.83 ng/mL in 2001 and 2006, respectively, whereas fPSA values for the tested specimens ranged from 0.02 to 5.72 and 0.00 to 5.92, respectively. Deming regression analyses showed agreement in assay values over time as tPSA values yielded a slope of 1.0112 and a y-intercept of 0.0195; fPSA values produced a slope 1.0538 and a y-intercept of –0.0442; f/tPSA values yielded a slope of 0.9631 and a y-intercept of 0.1195. A Bland-Altman analysis of the data demonstrated analyte and ratio stability over this time period. We conclude that serum, when collected properly and stored at –70°C or lower temperature, may be used for tPSA and fPSA clinical studies for at least 5 years after collection.
JemalA., SiegalR., WardE., MurrayT., XuJ., ThunM.J.. Cancer statistics, 2007.CA Cancer J Clin2007; 57: 43–66.
2.
BedzykW.D., LarsenB., GutteridgeS., BallasR.A.. Molecular mass determination for prostate-specific antigen and α1-antichymotrypsin complexed in vitro.Biotechnol Appl Biochem1998; 27: 249–57.
3.
OesterlingJ.E.. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.J Urol1991; 145: 907–23.
ChristenssonA., BjorkT., NilssonO.. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer.J Urol1993; 150: 100–5.
6.
StenmanU.H., LeinonenJ., AlfthanH., RannikkoS., TuhkanenK., AlfthanO.. A complex between prostate-specific antigen and c1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.Cancer Res1991; 51: 222–6.
7.
LudererA.A., ChenY.T., SorianoT.F.. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.Urology1995; 46: 187–94.
8.
CatalonaW.J., SmithD.S., WolfertR.L.. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.JAMA1995; 274: 1214–20.
9.
PearsonJ.D., LudererA.A., MetterE.J.. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.Urology1996; 48(Suppl 6A): 4–9.
10.
FroschermaierS.E., PilarskyC.P., WirthM.P.. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma.Urology1996; 47: 525–8.
11.
MarleyG.M., MillerM.C., KattanM.W.. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.Urology1996; 48(Suppl 6A): 16–22.
12.
PartinA.W., CatalonaW.J., SouthwickP.C., SubongE.N., GasiorG.H., ChanD.W.. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.Urology1996; 48(Suppl 6A): 55–61.
13.
ChenY.T., LudererA.A., ThielR.P., CarlsonG., CunyC.L., SorianoT.F.. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer.Urology1996; 47: 518–24.
14.
CatalonaW.J., PartinA.W., SlawinK.M.. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.JAMA1998; 279: 1542–7.
15.
WoodrumD., FrenchC., ShamelL.B.. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions.Urology1996; 48(Suppl 6A): 33–9.
16.
WoodrumD., YorkL.. Two-year stability of free and total PSA in frozen serum samples.Urology1998; 52: 247–51.
17.
PiironenT., PetterssonK., SuonpääM.. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to α1-antichymotrypsin in blood samples.Urology1996; 48(Suppl 6A): 81–7.
18.
ArcangeliC.G., SmithD.S., RatliffT.L., CatalonaW.J.. Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures.J Urol1997; 158: 2182–7.
19.
JungK., von KlinggräffP., BruxB., SinhaP., SchnorrD., LoeningS.A.. Preanalytical determinants of total and free prostate specific antigen and their ratio: blood collection and storage conditions.Clin Chem1998; 44: 685–8.
20.
JungK., LeinM., BruxB., SinhaP., SchnorrD., LoeningS.A.. Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions.Clin Chem Lab Med2000; 38: 1271–5.
21.
LeinonenJ., StenmanU-H. Reduced stability of prostate-specific antigen after long-term storage of serum at –20°C.Tumour Biol2000; 21: 46–53.
22.
UlmertD., BeckerC., NilssonJ-Å. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at –20°C.Clin Chem2006; 52: 235–9.
23.
PausE., NilssonO., BormerO.P., FossaS.D., OtnesB., SkovlundE.. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.J Urol1998; 159: 1599–605.
24.
CartledgeJ.J., ThompsonD., VerrilH., ClarksonP., EardleyI.. The stability of free and bound prostate-specific antigen.BJU Int1999; 84: 810–4.
25.
SokollL.J., BruzekD.J., DuaR.. Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen.Urology2002; 60(Suppl 4A): 24–30.
26.
SimmB., GleesonM.. Storage conditions for serum for estimating prostate-specific antigen.Clin Chem1991; 37: 113–4.
27.
DemingW.E.. Statistical adjustment of data.Mineola, NY: Dover Publications, 1984.
ArmitageP., BerryG., MatthewsJ.N.S.. Statistical methods in medical research, 4th ed.Malden, MA: Blackwell Science, 2002.
30.
BlandJ.M., AltmanD.G.. Statistical methods for assessing agreement between two methods of clinical measurement.Lancet1986; 1: 307–10.
31.
BlandJ.M., AltmanD.G.. Measuring agreement in method comparison studies.Stat Methods Med Res1999; 8: 135–60.
32.
DewitteK., FierensC., StöcklD., ThienpontL.M.. Application of the Bland-Altman plot for interpretation of method-comparison studies: a critical investigation of its practice [Letter].Clin Chem2002; 48: 799–801.
